137 results about "Mood disorders" patented technology

The invention provides a method for constructing a mood disorder assessment model based on hierarchical multilevel gating, which comprises the following steps: acquiring electroencephalogram signals of a plurality of testees, labeling labels, and constructing a first training sample set; training by using the first training sample set to obtain time sequence dynamic graph network feature extraction models corresponding to the multiple electroencephalogram parameter combinations and related time sequence dynamic graph network features; constructing a second training sample set by using the first training sample set and the time sequence dynamic graph network features, and training a hierarchical multilevel gating model; and obtaining a mood disorder assessment model based on the time sequence dynamic graph network feature extraction model and the hierarchical multi-level gating model corresponding to each electroencephalogram parameter combination. According to the method, the problem that the assessment accuracy is limited due to the fact that a mood disorder assessment model in the prior art does not consider the correlation between different parameter combinations among the brain region, the frequency band and the observation time length and the task and does not perform hierarchical screening on different parameter brain networks based on the task correlation is solved.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The invention provides a mood disorder assessment system based on multi-level feature fusion, and the system comprises a data collection unit which is used for collecting electroencephalogram signals of a plurality of brain regions of a to-be-assessed patient; the electroencephalogram feature extraction unit is used for extracting electroencephalogram features corresponding to the electroencephalogram signals of the brain regions; the multi-level feature extraction unit is constructed on the basis of the symptom features of the multiple testees and the corresponding electroencephalogram features, and is used for performing multi-level electroencephalogram feature latent variable extraction on the electroencephalogram features of the brain regions of the patient to be evaluated to obtain multi-level electroencephalogram feature latent variables; and the feature fusion and classification unit is used for carrying out classification prediction based on the electroencephalogram feature latent variables to obtain a mood disorder assessment result of the patient to be assessed. The method solves the problem that a mood disorder assessment system in the prior art adopts a single feature extraction and learning strategy and has no constraint of symptom information, so that the recognition capability of a model for mood disorders of different functional abnormality types is limited.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving cognition, emotion, memory and depression states and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by mass: radix scutellariae, rhizoma coptidis, radix puerariae, rhizoma anemarrhenae, bitter gourd, rhizoma zingiberis, stiff silkworm, American ginseng and radix notoginseng. Wherein the radix scutellariae and the rhizoma coptidis are monarch drugs and mainly attack the core pathogenesis; the radix puerariae, the rhizoma anemarrhenae and the pseudo-ginseng serve as ministerial drugs, assist monarch drugs and treat secondary pathogenesis; bitter gourd, rhizoma zingiberis, stiff silkworm and American ginseng are used as adjuvant drugs to regulate drug properties and treat and treat both symptoms and root causes; and radix puerariae and pseudo-ginseng are used as conductant drugs for guiding channels or harmonizing the drugs. The traditional Chinese medicine composition disclosed by the invention can be used for preventing and treating cognitive disorder, mood disorder and depressive state caused by metabolic disorder. The traditional Chinese medicine composition is small in side effect, high in individuation and suitable for being taken for a long time, and has an obvious treatment effect.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or nutritional compositions comprising the combination. The combination or compositions are for use in treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child. The mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL). The present invention also relates to the use of a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child, wherein the mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL).

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The invention relates to the field of medicines, and discloses a novel human PYY analogue, and compared with a PYY3-36 natural sequence, the novel human PYY analogue has a remarkable effect on improving metabolic diseases such as obesity, diabetes and fatty liver and emotional diseases such as anxiety disorder and depression.

This invention discloses a method for screening or assessing the risk of GLP-1 receptor agonist-related mood disorders. It reveals for the first time that TTR is a key molecular switch for the bidirectional mood effects of GLP-1 receptor agonists, and its expression level needs to be maintained within a specific physiological window to ensure mood homeostasis. This invention assesses the risk of developing mood disorders after using GLP-1 receptor agonists by detecting the expression level or activity of TTR in subjects. This invention also provides kits for assessing the mood side effects of GLP-1 receptor agonists, methods for screening candidate drugs for the prevention or treatment of related mood disorders, and pharmaceutical compositions containing TTR or its agonists. This invention elucidates the molecular mechanism by which GLP-1 receptor agonists inhibit TTR expression through the cAMP / PKA / Gli3 signaling pathway, thereby affecting the ERK / CREB pathway and synaptic plasticity, providing novel targets and strategies for precise drug use, risk warning, and intervention for related mood disorders using GLP-1 receptor agonists.

The invention provides application of hippophae rhamnoides fruit extract in preparation of products for preventing and treating cognitive dysfunction and / or emotional disorder and improving memory, and belongs to the technical field of biological medicine. The invention provides application of a sea-buckthorn extract or a product containing the sea-buckthorn extract in preparation of a product for preventing and treating cognitive dysfunction and / or mood disorder and improving memory. The sea-buckthorn extract comprises sea-buckthorn fruit oil, sea-buckthorn seed oil and / or sea-buckthorn fruit pulp. The hippophae rhamnoides extract is prepared from natural food hippophae rhamnoides rich in nutrient substances, has remarkable prevention and treatment effects on cognitive dysfunction and / or emotional disorder, has the effect of improving memory, can replace traditional medicine treatment, and has the advantages of being small in side effect, economical, practical, suitable for being taken for a long time and good in compliance.

Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.

The invention concerns methods for treating mood disorders such as depressive disorder or episodes, or other mood disorders with current depressive episodes, by administration of a leptin receptor agonist, such as metreleptin. The invention further shows amelioration of depressive disorder or episode and related conditions in patients suffering from depression as a primary disorder, or a depressive disorder or episode as a secondary disorder and / or comorbidity. The invention also concerns methods for treating a depressive episode, or a depressive disorder.

The invention discloses application of securinine in preparation of a medicine for relieving anxiety disorder of postmenopausal women. Female menopausal related mood disorder diseases are researched by constructing a bilateral ovariectomy mouse model, and mouse anxiety-like behaviors induced by ovariectomy can be quickly relieved within 30 minutes by single administration of a natural product securinine. The invention provides a medicine for treating postmenopausal female anxiety disorder, the medicine takes effect quickly, not only provides a brand new medicine candidate for quick intervention of menopausal related anxiety, but also defines a corresponding medication scheme, and has practical application potential.

The present disclosure discloses a composition of GLP-1 and PYY3-36 polypeptide analogues, a preparation method and use thereof, and relates to the technical field of biomedicines. The composition includes a GLP-1 polypeptide analogue and a PYY3-36 polypeptide analogue. Compared with the natural sequence of GLP-1 and the natural sequence of PYY3-36, the composition of the GLP-1 polypeptide analogue and the PYY3-36 polypeptide analogue has remarkable effects in ameliorating metabolic diseases such as obesity, diabetes mellitus, and fatty liver, and mood disorders such as anxiety and depression.

The present description relates to a method for treating a patient having a mood disorder, comprising administering to a subject in need a pharmaceutical composition comprising a base compound consisting substantially of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specified dosage regimen.

5-HT2A receptor ligands and receptor-ligand complexes are synthesized. These ligands, which may link two indole containing moieties through an amine, may be used in therapeutically effective amounts, to treat mood disorders and neurologic disorders.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

To provide dosage forms and compositions useful for preventing and / or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)).SOLUTION: Provided is an oral dosage form comprising: a compound of the following formula or a pharmaceutically acceptable salt thereof; and a modified-release polymer.SELECTED DRAWING: None

The invention relates to a bifidobacterium composition for relieving mood disorder caused by constipation and application of the bifidobacterium composition, and belongs to the technical field of probiotics. According to the bifidobacterium composition containing the animal bifidobacterium subsp. Lactis Bb-12 and the bifidobacterium longum subsp. Longum BB536, through the synergistic effect of the Bb-12 and the BB536, the effect of relieving constipation can be achieved by improving the water content of excrement, improving the intestinal tract movement capacity and increasing the content of short-chain fatty acid in the intestinal tract. On the basis that constipation is relieved, emotional disorders caused by constipation can be further relieved, and particularly, the content of anxiety and depression related cranial nerve factors BDNF in hippocampus is increased, and the relative expression quantity of inflammatory factors TNF-alpha is reduced. A new thought is provided for the development of nutritional supplement food for relieving anxiety and depression caused by constipation.

The invention discloses a multi-mode mood disorder classification method based on fMRI and voice, and the method mainly aims at constructing an fMRI and voice interaction fusion network framework which is composed of three stages of network structures, namely, a double-branch feature extraction network used for carrying out the feature extraction of voice data and fMRI signals, and a multi-branch feature extraction network used for carrying out the feature extraction of the voice data and the fMRI signals. The feature interaction fusion network is used for converting the multi-modal features into fusion features containing key information of data of each modal, and the full connection layer network is used for mapping the fusion features to category probabilities. A brain network topological structure and voice features which are related to mood disorder classification tasks and have high discrimination capability are effectively extracted from fMRI and voice data; therefore, cross-modal causal association between the fMRI and the voice data is effectively mined, and high-precision and interpretable mood obstacle recognition and classification are realized.

The application discloses application of a Hepcidin modulator. Abnormal increase of Hepcidin in a ventral hippocampus region in a senescence process drives imbalance of iron homeostasis of neurons, and further induces an anxiety-like phenotype. Pharmacodynamic verification shows that administration of a Hepcidin inhibitor to cells of the ventral hippocampus can effectively reverse anxiety behavior of a senescence model animal. The pharmaceutical composition described in the application takes the Hepcidin pathway as an intervention target, and an active ingredient thereof is selected from the following: (1) a high-affinity Hepcidin inhibitor NOX-H94; and (2) a recombinant adeno-associated virus vector carrying a Hepcidin-targeted interference sequence, which is used for silencing expression of Hepcidin in neurons of the ventral hippocampus in vivo. The above-mentioned preparation provides a new molecular target and a drug candidate for clinical intervention of senescence-related emotional disorders.

The present invention relates to a biomarker for distinguishing mood disorder-type psychiatric diseases and schizophrenia, and uses thereof. Based on a biomarker composition for mood disorder-type psychiatric diseases and schizophrenia comprising the serum proteins including leptin, tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), and brain-derived neurotrophic factor (BDNF), the present invention describes a composition for distinguishing mood disorder-type psychiatric diseases and schizophrenia, comprising reagents for measuring the expression levels of the five biomarker proteins, and a method for providing information for distinguishing between mood disorder-type psychiatric diseases and schizophrenia, using same.

The present disclosure relates to the field of medicine and discloses a novel human PYY3-36 analog. Compared with the naturally-occurring sequence of PYY3-36, the analog has a remarkable effect on ameliorating metabolic diseases such as obesity, diabetes and fatty liver, and on mood disorders such as anxiety and depression.